Cytokinetics Current Liabilities Trend from 2010 to 2022

CYTK -  USA Stock  

USD 47.25  0.22  0.46%

Cytokinetics Current Liabilities is increasing with slightly volatile movements from year to year. Current Liabilities is estimated to finish at about 77.5 M this year. For the period between 2010 and 2022, Cytokinetics, Current Liabilities quarterly trend regression had mean deviation of 14,854,581 and r-value of  0.83. Cytokinetics Selling General and Administrative Expense is increasing as compared to previous years. The last year's value of Selling General and Administrative Expense was reported at 96.8 Million.
  
Refresh
Check Cytokinetics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Cytokinetics main balance sheet or income statement drivers, such as Gross Profit of 59.3 M, Interest Expense of 17.7 M or Operating Expenses of 277 M, as well as many exotic indicators such as Interest Coverage of 7.48, Long Term Debt to Equity of 1.16 or PPandE Turnover of 7.99. Cytokinetics financial statements analysis is a perfect complement when working with Cytokinetics Valuation or Volatility modules. It can also supplement various Cytokinetics Technical models. Continue to the analysis of Cytokinetics Correlation against competitors.

Cytokinetics Quarterly Current Liabilities

66.85 Million

Share

Cytokinetics Current Liabilities Breakdown

Showing smoothed Current Liabilities of Cytokinetics with missing and latest data points interpolated. The current portion of Total Liabilities; reported if the company operates a classified balance sheet that segments current and non-current liabilities.Cytokinetics' Current Liabilities historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Cytokinetics' overall financial position and show how it may be relating to other accounts over time.
ViewLast Reported 31.65 M10 Years Trend
Increasing
Slightly volatile
 Current Liabilities 
Share
      Timeline 

Cytokinetics Current Liabilities Regression Statistics

Arithmetic Mean 30,231,397
Geometric Mean 22,248,156
Coefficient Of Variation 73.79
Mean Deviation 14,854,581
Median 26,704,000
Standard Deviation 22,309,187
Range 72,941,158
R-Value 0.83
R-Squared 0.69
Significance 0.00044001
Slope 4,757,104

Cytokinetics Current Liabilities History

20127.1 M
201326.7 M
201423.9 M
201531.6 M
201633.3 M
201732.4 M
201822.2 M
201926 M
202031.2 M
202171.9 M
202277.5 M

About Cytokinetics Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include Cytokinetics income statement, its balance sheet, and the statement of cash flows. Cytokinetics investors use historical funamental indicators, such as Cytokinetics's Current Liabilities, to determine how well the company is positioned to perform in the future. Although Cytokinetics investors may use each financial statement separately, they are all related. The changes in Cytokinetics's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Cytokinetics's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Cytokinetics Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Cytokinetics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for 2022
Current Liabilities71.9 M77.5 M
Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure and reldesemtiv, a skeletal muscle troponin activator, which is in Phase III clinical trial to treat amyotrophic lateral sclerosis and spinal muscular atrophy. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy and CK-3772271, a small molecule cardiac myosin inhibitor that is in Phase I clinical trial. Cytokinetics, Incorporated has a strategic alliance with Astellas Pharma Inc. The company was incorporated in 1997 and is headquartered in South San Francisco, California.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Cytokinetics without increasing your portfolio risk or giving up expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate.risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Pair Correlation Now

   

Pair Correlation

Compare performance and examine fundamental relationship between any two equity instruments
All  Next Launch Module

Pair Trading with Cytokinetics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Cytokinetics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Cytokinetics will appreciate offsetting losses from the drop in the long position's value.

Cytokinetics Pair Correlation

Correlation Analysis For Direct Indexing and Tax-loss Harvesting

The ability to find closely correlated positions to Cytokinetics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Cytokinetics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Cytokinetics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Cytokinetics to buy it.
The correlation of Cytokinetics is a statistical measure of how it moves in relation to other equities. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Cytokinetics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Cytokinetics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Cytokinetics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
Continue to the analysis of Cytokinetics Correlation against competitors. Note that the Cytokinetics information on this page should be used as a complementary analysis to other Cytokinetics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Portfolio Manager module to state of the art Portfolio Manager to monitor and improve performance of your invested capital.

Complementary Tools for Cytokinetics Stock analysis

When running Cytokinetics price analysis, check to measure Cytokinetics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cytokinetics is operating at the current time. Most of Cytokinetics' value examination focuses on studying past and present price action to predict the probability of Cytokinetics' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Cytokinetics' price. Additionally, you may evaluate how the addition of Cytokinetics to your portfolios can decrease your overall portfolio volatility.
Stock Screener
Find equities using custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Go
Analyst Recommendations
Analyst recommendations and target price estimates broken down by several categories
Go
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Go
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Go
Piotroski F Score
Get Piotroski F Score based on binary analysis strategy of nine different fundamentals
Go
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Go
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Go
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Go
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Go
Is Cytokinetics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cytokinetics. If investors know Cytokinetics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cytokinetics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
3.7 B
Quarterly Revenue Growth YOY
-0.82
Return On Assets
-0.19
Return On Equity
-2.8
The market value of Cytokinetics is measured differently than its book value, which is the value of Cytokinetics that is recorded on the company's balance sheet. Investors also form their own opinion of Cytokinetics' value that differs from its market value or its book value, called intrinsic value, which is Cytokinetics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cytokinetics' market value can be influenced by many factors that don't directly affect Cytokinetics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cytokinetics' value and its price as these two are different measures arrived at by different means. Investors typically determine Cytokinetics value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cytokinetics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.